84437-12-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Cyano-2-Hydroxy-Benzoic Acid Methyl Ester is used as an intermediate in the synthesis of pharmaceutical drugs for its ability to contribute to the formation of complex organic compounds, enhancing the development of new medications.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Cyano-2-Hydroxy-Benzoic Acid Methyl Ester serves as a key intermediate, facilitating the creation of a variety of complex compounds for diverse applications, including but not limited to chemical research and material development.

InChI:InChI=1/C9H7NO3/c1-13-9(12)7-4-6(5-10)2-3-8(7)11/h2-4,11H,1H3

Upstream product

• 4068-76-2 5-bromo-2-hydroxy-benzoic acid methyl ester 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 557-21-1 zinc(II) cyanide 
• 4068-75-1 methyl 5-iodosalicylate 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 152672-99-6 5-Cyano-2-hydroxy-N-(2-hydroxy-ethyl)-benzamide 
• 843675-67-2 methyl 5-cyano-2-(2-methoxy-2-oxoethoxy)benzoate 
• 10435-57-1 5-cyano-2-hydroxybenzoic acid 
• 1609429-12-0 5-cyano-2-(prop-2-yn-1-yloxy)benzoic acid 
• 1609428-71-8 5-cyano-N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-butyl)-2-(prop-2-ynyloxy)benzamide 
• 1609428-72-9 5-cyano-N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-butyl)-2-((1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzamide 
• 1609429-11-9 methyl 5-cyano-2-(prop-2-ynyloxy)benzoate 
• 1093397-34-2 methyl 3-amino-5-cyano-2-hydroxybenzoate 
• 1093397-35-3 methyl 5-cyano-2-hydroxy-3-nitrobenzoate 
• 1334481-35-4 Methyl 2-(2-(tert-butoxycarbonylamino)ethoxy)-5-cyanobenzoate 
• 518978-03-5 5-cyano-2-[(phenylmethyl)oxy]benzoic acid 
• 1285513-43-0 5-cyano-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 518978-02-4 methyl 5-cyano-2-[(phenylmethyl)oxy]benzoate 
• 1141474-14-7 methyl 5-[amino(hydroxyimino)methyl]-2-hydroxybenzoate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

ALKYNYL ARYL CARBOXAMIDES

The present invention is related to alkynyl aryl carboxamides of Formula (I’) and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance. insulin resistance, hyperlipidemia, hypertriglyceridemia- hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkynyl aryl carboxamides of Formula (I’) to modulate, notably to inhibit the activity of PTPs. (I’) A is a C2-C15 alkynyl, C2-C6-alkynyl aryl, C2-C6-alkynyl heteroaryl. Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group; n is either 0 or 1. Cy' is an aryl., which may optionally be fused by a 3-8 membered cycloalkyl. R1and R2 are independently from each other is selected from the group consisting of hydrogen or (CI-C6)alkyl. R4and R5 are each independently from each other selected from the group consisting of H, hydroxy. C1 -C6 alkyl, carboxy, C1-C6 alkoxy, C1 -C3 alkyl carboxy, C2-C3 alkenyl carboxy, C2-C3 alkynyl carboxy, amino or R4 and R5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R4 or R5 is not a hydrogen or C1-C6 alkyl.

ARYL DICARBOXAMIDES

The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycernia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an airninocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R1 and R2 are independently from each other is selected from the group consisting of hydrogen or C1-C6-alkyl; R4 and R5 are each independently from each other selected from the group consisting of H, hydroxy, C1-C6 alkyl, carboxy, C1-C6 alkoxy, C1-C3 alkyl carboxy, C2-C3 alkenyl carboxy, C2-C3 alkynyl carboxy, amino or R4 and R5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R4 or R5 is not a hydrogen or C1-C6 alkyl.

Application of polymer-supported triphenyl phosphine in the palladium-catalyzed cyanation reaction under microwave conditions

A variety of aryl nitriles were prepared in excellent yields from the palladium acetate catalyzed coupling of aryl halides with Zn(CN)2 using polymer-supported triphenyl phosphine as the ligand and dimethylformamide as solvent under microwave irradiation conditions.

Bispidine compounds useful in the treatment of cardiac arrythmias

There is provided compounds of formula I, 1 wherein R1, R2, R3, R4, R5, R6, R7, R41, R42, R43 R44, R45, R46, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Bispidine antiarrhythmic compounds

There is provided a compound of formula I, wherein R1, R2, R9, R10, R11, R12, X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives

A novel series of platelet receptor glycoprotein (Gp) IIb/IIIa antagonists with condensed heterocycles as their basic core was synthesized. In an in vitro assay, trans-4-(5-amidinobenzofuran-2- carboxamido)cyclohexyl]oxyacetic acid 17e and trans-3-[4-(5-

CARBOXYLIC ACID COMPOUND HAVING CONDENSED RING, SALT THEREOF AND PHARMACEUTICAL USE THEREOF

A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases